Alexion Pharmaceuticals Got Some Good News

By Jason Carr

Morgan Stanley analyst Matthew Harrison upgraded Alexion Pharmaceuticals (NASDAQ: ALXN) to Buy today. The company’s shares closed yesterday at $101.08, close to its 52-week low of $98.63.

According to TipRanks.com, Harrison is a 4-star analyst with an average return of 9.3% and a 59.3% success rate. Harrison covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Syndax Pharmaceuticals Inc, and Achillion Pharmaceuticals.

Currently, the analyst consensus on Alexion Pharmaceuticals is Strong Buy and the average price target is $157.43, representing a 55.7% upside.

In a report issued on May 11, BMO Capital also reiterated a Buy rating on the stock with a $158 price target.

The company has a one year high of $157.02 and a one year low of $98.63. Currently, Alexion Pharmaceuticals has an average volume of 2.29M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in New Haven, CT.